A preliminary controlled trial of divalproex in posttraumatic stress disorder

Annals of Clinical Psychiatry

Volumn 21, Issue 2, 2009, Pages 89-94

  Hamner, Mark B ^a   Faldowski, Richard A ^b   Robert, Sophie ^a   Ulmer, Helen G ^a   Horner, Michael David ^a   Lorberbaum, Jeffrey P ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Anticonvulsant; Divalproex; Mood stabilizer; Posttraumatic stress disorder; Psychopharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; VALPROIC ACID;

ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; STRESS DISORDERS, POST-TRAUMATIC; VALPROIC ACID;

EID: 70349581040     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with acute and chronic posttraumatic stress disorder. Arlington, VA: American Psychiatric Association; 2004.
2. PTSD Treatment Guidelines Task Force. Guidelines for treatment of PTSD. J Trauma Stress. 2000;13: 539-588.
3. Veterans Administration/Department of Defense Clinical Practice Guideline Working Group. Management of post-traumatic stress. Washington, DC: Veterans Health Administration, Department of Veterans Affairs and Health Affairs, Department of Defense; 2003. Office of Quality and Performance publication 10Q-CPG/PTSD-04.
4. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement update on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2004;65(suppl 1):55-62.
5. Treatment of posttraumatic stress disorder. Expert Consensus Panels for PTSD. J Clin Psychiatry. 1999;60(suppl 16):3-76.
6. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45:1226-1229. (Pubitemid 29236566)
7. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy 0and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68: 201-206. (Pubitemid 46362640)
8. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007;27:677-681. (Pubitemid 351339456)
9. Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007;27:85-88. (Pubitemid 46105772)
10. Berlant JL. Topiramate in posttraumatic stress disorder: preliminary clinical observations. J Clin Psychiatry. 2001;62(suppl 17):60-63. (Pubitemid 32720668)
11. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63:15-20. (Pubitemid 34113481)
12. Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry. 2004;4:24.
13. Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry. 2003;64:1421-1425. (Pubitemid 41270099)
14. Connor KM, Davidson JR, Weisler RH, et al. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl). 2006;184:21-25. (Pubitemid 43005753)
15. Lipper S, Davidson JR, Grady TA, et al. Preliminary study of carbamazepine in posttraumatic stress disorder. Psychosomatics. 1986;27:849-854. (Pubitemid 17224123)
16. Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans: clinical and EEG findings, possible therapeutic effects of carbamazepine. Biol Psychiatry. 1988;23:642-644. (Pubitemid 18064915)
17. Bremner JD, Mletzko T, Welter S, et al. Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. J Clin Psychiatry. 2004;65:1559-1564.
18. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;113:141-146. (Pubitemid 34020148)
19. Kinrys G, Wygant LE, Pardo TB, et al. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry. 2006;67:211-214. (Pubitemid 43357466)
20. Harvey BH, Oosthuizen F, Brand L, et al. Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology (Berl). 2004;175:494-502. (Pubitemid 39362049)
21. Harvey BH, Bothma T, Nel A, et al. Involvement of the NMDA receptor, NO-cyclic GMP, and nuclear factor K-beta in an animal model of repeated trauma. Human Psychopharmacology. 2005;20:367-373. (Pubitemid 41093940)
22. Chambers RA, Bremner JD, Moghaddam B, et al. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry. 1999;4:274-281.
23. Vaiva G, Thomas P, Ducrocq F, et al. Low posttrauma GABA plasma levels as a predictive factor in the development of acute posttraumatic stress disorder. Biol Psychiatry. 2004;55:250-254. (Pubitemid 38117160)
24. Cunningham MO, Woodhall GL, Jones RS. Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro. Neuropharmacology. 2003;45:907-917. (Pubitemid 37297916)
25. Gobbi G, Janiri L. Sodium- and magnesium-valproate in vivo modulate glutaminergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacology (Berl). 2006;185:255-262. (Pubitemid 43363622)
26. Laeng P, Pitts RL, Lemire AL, et al. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J Neurochem. 2004;91:238-251. (Pubitemid 39314954)
27. Berigan TR, Holzgang A. Valproate as an alternative in post-traumatic stress disorder: a case report. Mil Med. 1995;160:318.
28. Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry. 1991;148:1086-1087.
29. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991;52:361-364.
30. Clark RD, Canive JM, Calais LA, et al. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress. 1999;12:395-401. (Pubitemid 29279497)
31. Petty F, Davis LL, Nugent AL, et al. Valproate therapy for chronic, combat-induced posttraumatic stress disorder. J Clin Psychopharmacol. 2002;22:100-101. (Pubitemid 34101304)
32. Otte C, Wiedemann K, Yassouridis A, et al. Valproate monotherapy in the treatment of civilian with non-combat-related posttraumatic stress disorder: an openlabel study. J Clin Psychopharmacol. 2004;24:106-108. (Pubitemid 38134182)
33. Davis LL, Ambrose SM, Newell JM, et al. Divalproex for the treatment of posttraumatic stress disorder: a retrospective chart review. International Journal of Psychiatry in Clinical Practice. 2005;9:278-283. (Pubitemid 41658664)
34. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186-1197.
35. Davis LL, Davidson JR, Ward LC, et al. Divalproex in the treatment of post-traumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008;28:84-88.
36. Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.
37. Spitzer RL, Williams JBW, Gibbon M, et al. Structured clinical interview for DSM-IV (SCID-IV). New York, NY: Biometric Research, New York State Psychiatric Institute; 1994.
38. Blake DD, Weathers FW, Nagy LM, et al. A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. Behavior Therapist. 1990;18:187-188.
39. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41:209-218. (Pubitemid 9219271)
40. Guy W. ECDEU Assessment manual for psychopharmacology. Rev ed. Washington, DC: US Department of Health, Education, and Welfare; 1976.
41. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
42. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141-173.
43. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193-213. (Pubitemid 19144991)
44. Germain A, Hall M, Krakow B, et al. A brief sleep scale for posttraumatic stress disorder: Pittsburgh Sleep Quality Index Addendum for PTSD. J Anxiety Disord. 2005;19:233-244. (Pubitemid 39469094)
45. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52:1048-1060.